Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Recognizing the significant mobility challenges faced by many people with FOP, Pasatru can be administered across a range of care settings, including home infusion where appropriate. The recommended starting dosage is based on weight at 10 mg/kg and is given intravenously over 60 minutes once monthly (every four weeks) but may be decreased to a 3 mg/kg infusion over 60 minutes once monthly if not tolerated. Pasatru is a VelocImmune®-derived, ful

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.